Business
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
SOUTH SAN FRANCISCO, CALIF., March 24, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET.
About this update from Kezar Life Sciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1100,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/189f3d623149b53114835672b224964b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WVfbfMAzlJnB_GjkZ9hIMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/189f3d623149b53114835672b224964b","width":960,"height":314},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/h3KT2uI0VNyD2csrK4XRMw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIyMDA7aD03MjA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/189f3d623149b53114835672b224964b","width":1100,"height":360}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, CALIF., March 24, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis (AIH) on Tuesday, March 25, 2025, at 8:00 a.m. ET.","length":452,"tagName":"p"},{"type":"text","content":"The event will highlight topline data from Kezar’s PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of Medicine at Indiana University School of Medicine and a principal investigator on the PORTOLA trial, and Gideon Hirschfield, PhD, the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, and Director of the Francis Family Liver Clinic at Toronto General Hospital.","length":584,"tagName":"p"},{"type":"text","content":"A live question and answer session will follow the formal presentation.","length":71,"tagName":"p"},{"type":"text","content":"To access the live audio webcast with slides and dial-in information as needed, please register here: https://kezar-life-sciences-portola-phase-2a-topline-results.open-exchange.net/.","length":182,"tagName":"p"},{"type":"text","content":"A live webcast of the event can also be found on the Kezar website at https://ir.kezarlifesciences.com/news-events...